Developing Novel Monoclonal Antibody Therapeutics
TrueBinding Inc. is a clinical stage biotherapeutic company creating new and exciting molecules for applications in neurodegenerative and metabolic diseases, stroke, oncology and other areas with great unmet medical need.
Revolutionizing Patient Care
TrueBinding is optimizing patient care through its revolutionary pipeline of monoclonal antibody therapeutics, providing targeted treatments for a diverse range of diseases and medical conditions. By harnessing the power of our platform technology, we rapidly develop and deliver highly specific and effective monoclonal antibodies, ushering in a new era of precision medicine that holds the promise of improved patient outcomes and enhanced therapeutic options.
Accelerating Biopharmaceutical Innovation
TrueBinding's contract development and manufacturing services offer unparalleled benefits for clients in the biopharmaceutical industry. By leveraging our advanced technology and expertise, our teams can accelerate the development process, ensuring rapid and efficient production of high-quality monoclonal antibodies, ultimately enabling clients to bring their innovative therapies to market faster and more cost-effectively.
TB006 Expanded Access Program
Granting access to investigational medications, the Expanded Access Program (EAP) for TB006 offers a compassionate approach to providing potential benefits to patients who have exhausted all other alternatives combating Alzheimer’s Disease.
Completion of Phase 1b/2a Clinical Trial for Alzheimer's Disease
Topline data from a one-month TB006 treatment regimen shows improvements in Clinical Dementia Rating-Sum of Boxes (CDR-SB) in patients, indicating the potential of slowing or reducing clinical decline. Key secondary endpoints were consistent with the primary findings that TB006 improved cognition and function in patients
Latest News
April, 2024
The Hong Kong Department of Health has granted approval for the Named Patient Program for TB006, in treating dementia and Alzheimer’s disease. This program allows patients with these conditions to access TB006 outside of formal clinical trials, providing an opportunity for those who may not have other treatment options to benefit from our investigational drug.
May 26, 2024
The FDA has renewed the Expanded Access Program (NCT05959239) for TB006 in treating dementia and Alzheimer's disease. This renewal allows existing patients to continue receiving TB006 outside of traditional clinical trials and offers hope for patients seeking alternative treatment options.
July 9, 2024
The FDA has approved TrueBinding to proceed clinical trials for TB006, a new therapeutic candidate for treating adult autism spectrum disorder (ASD). The clinical trials (NCT06500637) will assess TB006’s safety and efficacy, offering hope for new, effective treatment options for those with ASD and potentially improving their quality of life.